Ubs Asset Management Americas Inc Syndax Pharmaceuticals Inc Transaction History
Ubs Asset Management Americas Inc
- $381 Billion
- Q3 2024
A detailed history of Ubs Asset Management Americas Inc transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 137,447 shares of SNDX stock, worth $2.21 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
137,447
Previous 153,360
10.38%
Holding current value
$2.21 Million
Previous $3.15 Million
15.98%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding SNDX
# of Institutions
227Shares Held
88.3MCall Options Held
1.01MPut Options Held
692K-
Black Rock Inc. New York, NY7.91MShares$127 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ5.84MShares$94.1 Million9.23% of portfolio
-
Wellington Management Group LLP Boston, MA4.99MShares$80.3 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.89MShares$78.7 Million0.0% of portfolio
-
Eversept Partners, LP New York, NY4.11MShares$66.1 Million6.25% of portfolio
About Syndax Pharmaceuticals Inc
- Ticker SNDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,565,200
- Market Cap $911M
- Description
- Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...